Last reviewed · How we verify
tetanus-CMV fusion peptide vaccine
tetanus-CMV fusion peptide vaccine is a Biologic drug developed by City of Hope Medical Center. It is currently in Phase 1 development.
At a glance
| Generic name | tetanus-CMV fusion peptide vaccine |
|---|---|
| Sponsor | City of Hope Medical Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (PHASE1)
- Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma (PHASE1)
- Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tetanus-CMV fusion peptide vaccine CI brief — competitive landscape report
- tetanus-CMV fusion peptide vaccine updates RSS · CI watch RSS
- City of Hope Medical Center portfolio CI
Frequently asked questions about tetanus-CMV fusion peptide vaccine
What is tetanus-CMV fusion peptide vaccine?
tetanus-CMV fusion peptide vaccine is a Biologic drug developed by City of Hope Medical Center.
Who makes tetanus-CMV fusion peptide vaccine?
tetanus-CMV fusion peptide vaccine is developed by City of Hope Medical Center (see full City of Hope Medical Center pipeline at /company/city-of-hope-medical-center).
What development phase is tetanus-CMV fusion peptide vaccine in?
tetanus-CMV fusion peptide vaccine is in Phase 1.